On March 28, 2022 Nanjing Kati Medical Technology Co., Ltd., a cutting-edge domestic solid tumor CAR-T cell therapy company, reported in early February 2022, the company completed an A+ round of financing totaling more than 70 million yuan (Press release, CART Medical, MAR 28, 2022, View Source [SID1234639848]). This round of financing was jointly completed by Nanjing Chengyi Investment, Qiandao Group, Suzhou Guanya Investment and Haihui Investment. This round of financing will be mainly used to promote IND filing for Kati Medical’s leading product.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kati Medical was established in 2017 and is headquartered in the Nanjing Biopharmaceutical Valley, a national-level Jiangbei New Area in Nanjing. It is a key enterprise in the genetic and life health fields and a national high-tech innovation enterprise in Jiangbei New Area. Kati Medical focuses on the development of new CAR-T cell drugs for solid tumors. Focusing on the solid tumor microenvironment, the proprietary technology platform has significant potential. Kati Medicine was founded by Dr. Wang Enxiu, a core member of Carl June’s team at the University of Pennsylvania. The company’s core leadership team comes from the Chinese Academy of Sciences, Tsinghua Union Medical College, Nanjing Medical University, and MD Anderson Cancer Center in the United States. Center and other top institutions have rich experience and high professionalism in oncology, drug research and development, commercial operations, etc. Dr. Wang Enxiu has achieved breakthrough results in CAR-T flexible activation design, and the core patent has been authorized by European, American and Chinese patents. Immune cell CAR-T drugs currently show significant efficacy in the clinical treatment of hematological tumors, but most current CAR-T products have poor efficacy against solid tumors. Dr. Wang pointed out that this is mainly related to the structural design of CAR. Solid tumors have a more complex microenvironment than hematological tumors. Without technological innovation, it is difficult to apply the structural design of traditional CAR to bring clinical efficacy. Cati Medical has identified this need and pain point, concentrated its efforts, designed the CAR-T architecture for the solid tumor microenvironment, and independently developed a new DAP-CAR-T solid tumor CAR-T technology platform. The DAP-CAR-T technology platform based on flexible activation can effectively improve the adaptability of CAR-T cells to the tumor microenvironment, reduce clinical side effects and have good durability. Kati Medical relies on its own technology platform to develop a series of new candidate R&D drugs with independent intellectual property rights. It has 5 R&D pipelines including KT030, KT032, KT095, KT081, and KT051. Among them, KT032 treats pancreatic cancer, ovarian cancer, and mesothelial cancer. Cancer and other solid tumors are designated as indications, and it is the leading research and development pipeline of Kati Medicine. KT032 is a solid tumor CAR-T product targeting Mesothelin. Early IIT data show that among 8 patients with mesothelin-positive solid tumors (one of which was pancreatic tumor and the rest were ovarian cancer), the best curative effect after treatment was PR (4/7), SD (3/7), and the overall response rate ( ORR) was 57.5%, the disease control rate (DCR) was 100%, the median progression-free survival was 7 months, and the longest progression-free survival was 17 months; the median survival was 11.625 months, and the longest survival The term is 17 months. Kati Medical is currently carrying out in-depth cooperation with top domestic hospitals. The number of patients enrolled in the trial continues to increase, forming a trial progress rate of one case recovery, one case preparation, and one case blood collection, and continues to collect trial data. Dr. Wang Enxiu, founder of Kati Medical, said: "Our vision is to be the most innovative cell drug company in China. Currently, Kati Medical has built a third-generation signaling platform for the "activation end" of CAR, which can realize target replacement at any time. , thereby expanding different indications. In the future, we will use our own innovative platform to open a richer product pipeline and achieve more diversified product transformation." Wang Yuan, partner of Nanjing Chengyi Investment, said: "Kati Medical The founder of Penn made a significant contribution to the collaboration between Penn and Novartis to promote the launch of the world’s first CAR-T drug. He has more than ten years of experience and accumulation in the field of CAR-T technology and is a trustworthy partner. In addition, , we attach great importance to Kati Medical’s own technology platform, based on which Kati Medical can establish a rich product pipeline for different solid tumors." Jiang Yu, investment director of Qiandao Investment Fund, said: "There are many fields in the field of gene and cell therapy. Opportunities for layout, CAR-T has shown good clinical efficacy in the treatment of hematological tumors, but there is still room for breakthrough in solid tumors. We recognize the accumulation and experience of Kati Medical and founder Dr. Wang Enxiu in the CAR-T field, and are optimistic about it The layout and prospects of the company’s product pipeline." About Chengyi Investment Chengyi Investment was founded in 2015, based in Nanjing and radiating to the Yangtze River Delta region. Focus on equity investment and value-added services in early and growth stages, with a core focus on biomedicine and technological innovation. At present, the scale of Chengyi Investment Management Fund is nearly 2 billion yuan. In the field of biomedicine, we have invested in a number of outstanding companies that represent the future development direction, including Zhonghui Biotech, Bioxin Biotech, and Kewang Pharmaceuticals. In addition to capital assistance, Chengyi Investment also provides all-round and multi-level help and support to each invested enterprise to promote enterprise innovation and growth, so that they can eventually develop into industry leaders and beneficially promote industrial change and social progress. About Gandao Group Gandao Group was founded in 2011. Adhering to the concept of "technology empowers finance, financial services industry, and industry serves the motherland", it is deeply involved in China’s economic development and industrial upgrading, and is committed to becoming a comprehensive holding company that leads innovation with technology and serves the real economy. group. Qandao focuses on multiple asset management and investment businesses such as equity investment, industrial investment, and special opportunity investment. The group owns Qandao Investment Fund Management Co., Ltd., which focuses on medicine and medical technology, advanced manufacturing, and new energy, as well as a subsidiary of a state-owned enterprise under mixed ownership reform— —China Emerging Asset Management Co., Ltd. and many other member companies. Qandao’s pharmaceutical and medical investment focuses on innovative drugs including biomedicine, in vitro diagnostics, innovative medical devices, medical services and technology. About Suzhou Crown Asia Investment Suzhou Guanfengyu Venture Capital Center (Limited Partnership) is a private equity investment fund managed by Crown Asia Investment. Crown Asia Investment is established by professionals with senior professional background, work experience and independent judgment. , has rich investment experience and resource accumulation in the fields of biomedicine and equipment, semiconductors and new energy. Guided by industrial development needs, based on hard-core technology investment, and relying on rich industrial resources, the company continuously discovers and cultivates outstanding innovative enterprises with growth potential, creates long-term value for investors, and supports the growth of innovative enterprises. Protect and protect. About Haihui Investment
Haihui Investment was established in 2007 and is headquartered in Guangzhou. It is the first venture capital fund in Guangzhou to obtain national registration and management. It is a venture capital institution (VC) that has long been focused on start-up companies. It has worked with Jiete Biotech, Hongya CNC, Boyun New Materials, Gaolan Shares, Lushan New Materials, etc. have dozens of successful IPO exit cases as early investors. The cumulative assets of its managed funds are tens of billions. It is the national technology-based small and medium-sized enterprise guidance fund recognized management agency, and has been continuously It has received key support from the National Venture Capital Guidance Fund Project for more than ten years.